The Extremely Substantial Lobbying Footprint of Greenwich Biosciences
Here’s Cannabis Wire’s introduction to their investigation..
The US subsidiary of GW Pharmaceuticals, behind the only FDA-authorized cannabis extract-primarily based medicine, is lobbying in all 50 states.
By Nikitha Sattiraju
Greenwich Biosciences, the United States subsidiary of the British GW Pharmaceuticals, registered to lobby in every single single state in the country—including ones exactly where all types of cannabis are prohibited—over the final 3 years. GW is the world’s oldest and biggest pharmaceutical corporation solely focused on generating medicines derived from cannabis plants, which it grows in Britain.
Greenwich Biosciences is also registered at the federal level, exactly where it spent upwards of $1 million lobbying on Meals and Drug Administration regulation of “cannabidiol in medicines and customer merchandise,” the “regulation of cannabis-primarily based medicine,” and on the “education and assistance for public policies connected to the analysis and improvement of, and access to, FDA-authorized therapies containing CBD or other cannabinoids.”
The corporation is also lobbying on top rated cannabis bills in Congress: the Secure Banking Act, which would give the booming business access to banks and other economic solutions and the STATES Act, which would get federal law out of the way in state-legal cannabis applications. Not to mention 1 bill that sailed via Congress, and was signed into law 1 year ago: “Regulations to implement 2018 Farm Bill Provisions,” is a further articulated priority. 1 of the lobbyists for Greenwich—Hazen Marshall with Marshall & Popp, LLC—is the former policy director for Senate Majority Leader Mitch McConnell, an outspoken hemp advocate who pushed the crop’s legalization via the 2018 Farm Bill.
Study the complete story on Cannabis Wire.